Treating Transplant-Ineligible Patients With HCC and Liver-Confined Disease

Opinion
Video

Focusing on liver-directed therapy, the panel provides clinical insights on the treatment of patients with hepatocellular carcinoma who have liver-confined disease and are not candidates for transplant.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.

Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC

Roman Fabbricatore
August 15th 2025
Article
Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
August 15th 2025
Podcast
HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.

HAIC Regimen Yields Long-Term Survival in Unresectable HCC

Russ Conroy
August 15th 2025
Article
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

FDA Approves SIR-Sphere Y-90 in HCC

Ariana Pelosci
August 15th 2025
Article
Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC

Roman Fabbricatore
August 15th 2025
Article
Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.

Hypofractionated RT Shows Portal Vein Tumor Thrombosis Control, OS in HCC

Roman Fabbricatore
August 15th 2025
Article